Table 1 Baseline characteristics, clinical presentation, CT scanning and treatment of patients with abdominal manifestations
Characteristics | Total N = 183 |
|---|---|
Male, N | 72 (39%) |
Age (years) | 42 [30–55] |
Asian, N | 183 (100%) |
Body mass index (kg/m2) | 22 [20–25] |
Comorbidities, N | |
 Hypertension | 14 (7.7%) |
 Diabetes mellitus | 13 (7.1%) |
 Dyslipidemia | 8 (4.4%) |
 Bronchial asthma | 14 (7.7%) |
 COPD | 1 (0.5%) |
 Cardiovascular disease | 6 (3.3%) |
 CKD | 4 (2.2%) |
 Liver disease | 3 (1.6%) |
 Gastrointestinal disease | 9 (4.9%) |
 Psychiatric disorder | 19 (10.4%) |
 Malignancy disease | 10 (5.5%) |
 Autoimmune disease | 8 (4.4%) |
Abdominal manifestations, N | |
 Nausea and vomiting | 86 (47%) |
 Abdominal pain | 63 (34%) |
 Diarrhea | 61 (33%) |
 Gastrointestinal bleeding | 20 (11%) |
 Anorexia | 6 (3.3%) |
Extra-abdominal manifestations, N | |
 Cough or sputum | 90 (49%) |
 Fever | 78 (43%) |
 Sore throat | 65 (36%) |
 Headache | 43 (23%) |
 Fatigue | 33 (18%) |
 Dysgeusia | 4 (2.2%) |
 Dysosmia | 1 (0.5%) |
Vaccination frequency, N | |
 < 2 | 58 (32%) |
 2 | 58 (32%) |
 3 | 58 (32%) |
 4 | 5 (2.2%) |
 Missing data | 4 (2.2%) |
CT scan, N | |
 None | 36 (20%) |
 Chest | 58 (32%) |
 Chest and abdominal | 89 (49%) |
Treatment, N | |
 Nirmatrelvir/ritonavir | 9 (4.9%) |
 Remdesivir | 26 (14%) |
 Molnupiravir | 16 (8.7%) |
 Sotrovimab | 15 (8.2%) |
 Casirivimab and imdevimab | 17 (9.3%) |
 Steroid | 2 (1.1%) |
 Onset to presentation (days) | 4 [2–6] |
Origin, N | |
 None | 146 (80%) |
 Public health center | 33 (18%) |
 Clinic | 4 (2.2%) |
 Hospital | 0 (0%) |
Hospitalization, N | |
 Yes | 28 (15%) |
 No | 155 (85%) |